<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776828</url>
  </required_header>
  <id_info>
    <org_study_id>CILON-T</org_study_id>
    <nct_id>NCT00776828</nct_id>
  </id_info>
  <brief_title>The Efficacy of CILostazol ON Ischemic Complications After DES Implantation</brief_title>
  <acronym>CILON-T</acronym>
  <official_title>Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives :

        -  To evaluate the influence of concomitant use of cilostazol with aspirin and clopidogrel
           on the composite cardiovascular adverse outcomes (cardiac death, myocardial infarction,
           nonhemorrhagic stroke, target lesion revascularization) after drug-eluting stent
           implantation

      Study Design : Prospective, open label, two arm, randomized multicenter trial to test the
      superiority of cilostazol group compared with the control group. Patients will be randomized
      according to the use of cilostazol

      Patient Enrollment: 960 patients enrolled at 5 centers in Korea

      Patient Follow-up : Clinical follow-up will occur at 1, 3 and 6 months. Angiographic
      follow-up will be recommended to all patient at 6 months after index procedure.

      Primary Endpoint

        -  Composite of adverse cardiovascular/cerebrovascular outcomes (cardiac death, myocardial
           infarction, nonhemorrhagic stroke, target lesion revascularization) within 6 months

      Secondary Endpoint

        -  All cause of death, stent thrombosis, and each component of primary endpoint at six
           months

        -  PRU level measured at discharge after the index procedure and after six months

      Safety Endpoint

        -  Bleeding complications according to TIMI criteria

        -  The incidence of drug discontinuation

        -  Heart rate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stratified randomization by statin type (rosuvastatin or atorvastatin) and the center was
      performed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of adverse cardiovascular outcomes</measure>
    <time_frame>six months</time_frame>
    <description>composite of cardiac death, myocardial infarction, ischemic stroke and target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause of death</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each component of primary endpoint</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRU level</measure>
    <time_frame>at discharge after the index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRU level</measure>
    <time_frame>six months after the index procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">960</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>TAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triple antiplatelet therapy : aspirin, clopidogrel and cilostazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dual antiplatelet therapy : aspirin, clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>Pletaal (Otsuka Pharm.) 100mg bid for six months</description>
    <arm_group_label>TAT</arm_group_label>
    <arm_group_label>DAT</arm_group_label>
    <other_name>Pletaal (Otsuka pharmaceutical)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be at leat 18 years of age

          -  Subject is able to verbally confirm understandings of risks, benefits and treatment
             alternatives of cilostazol and he/she or his/her legally authorized representative
             provides written informed consent prior to any study related procedure.

          -  Subject must have significant coronary artery stenosis (&gt;50% by visual estimate)

          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,
             recent infarction, silent ischemia, positive functional study or reversible changes in
             the electrocardiogram (ECG) consistent with ischemia. In subjects with coronary artery
             stenosis&gt;75%, evidence of myocardial ischemia does not have to be documented.

          -  Coronary lesions must be amenable for percutaneous coronary revascularization with
             drug eluting stents.

        Exclusion Criteria:

          -  Subject who undergoes primary percutaneous coronary intervention due to acute ST
             elevation myocardial infarction

          -  Subject who has contraindication or allergy to anti-platelet agents (aspirin,
             clopidogrel or cilostazol)

          -  Subject who has thrombocytopenia (&lt;120,000/uL)

          -  Subject who has liver cirrhosis (Child class B or C)

          -  Subject who is on the anticoagulation therapy

          -  Subject who has severe congestive heart failure (left ventricular ejection fraction
             &lt;30%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-Ho Chae, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jang-Ho Bae, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gonyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Chan Cho, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-Woon Rha, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>cilostazol</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>statin</keyword>
  <keyword>drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

